What is RefleXion?
RefleXion operates at the intersection of advanced oncology and precision engineering. By focusing on biotargeting, the company aims to overcome the traditional limitations of radiation therapy, offering a more targeted approach to cancer treatment. Its core technology is designed to improve patient outcomes by minimizing damage to healthy tissue while maximizing the efficacy of therapeutic interventions. As a key player in the life sciences sector, RefleXion is not merely a hardware provider but a comprehensive solution architect for modern oncology departments, integrating sophisticated software and diagnostic capabilities into its clinical offerings.
How much funding has RefleXion raised?
RefleXion has raised a total of $587.6M across 8 funding rounds:
Series A
$11.6M
Series B
$6M
Series C
$100M
Unspecified
$60M
Private Equity
$100M
Private Equity
$80M
Debt
$125M
Other Financing Round
$105M
Series A (2014): $11.6M with participation from Venrock and Sofinnova Partners
Series B (2016): $6M led by Venrock, Pfizer Venture Investments, Sofinnova Partners, and KCK
Series C (2018): $100M supported by KCK, Venrock, The Rise Fund, GT Healthcare Capital Partners, Pfizer Venture Investments, and Sofinnova Partners
Unspecified (2019): $60M featuring Oxford Finance
Private Equity (2020): $100M backed by Public Sector Pension Investment Board
Private Equity (2022): $80M with participation from KCK Group, T. Rowe Price, PSP Investments, and The Rise Fund
Debt (2022): $125M led by Oxford Finance
Other Financing Round (2023): $105M supported by Ally Bridge Group, Squarepoint Capital, TPG, The Rise Fund, Pictet Asset Management, Johnson & Johnson Services Inc, T. Rowe Price, and Pfizer
Key Investors in RefleXion
Venrock
A historic venture capital firm based in Palo Alto, Venrock provides strategic guidance and entrepreneurial support to high-growth healthcare and technology ventures.
Sofinnova Partners
A leading European venture capital firm specializing in life sciences, Sofinnova acts as a hands-on partner for transformative innovations across the entire healthcare value chain.
The Rise Fund
An impact investing platform that focuses on growth-stage, mission-driven companies aligned with global sustainability goals, particularly within the healthcare sector.
What's next for RefleXion?
With the recent injection of $105M, RefleXion is well-positioned to transition into its next phase of commercial expansion and clinical validation. The company is expected to leverage this capital to broaden its market reach, enhance its R&D pipeline, and potentially explore new therapeutic applications for its biotargeting technology. Given the involvement of major biopharmaceutical and institutional investors, the firm is likely to prioritize strategic partnerships that facilitate global distribution and long-term sustainability in the healthcare market. The focus remains on scaling its impact-driven mission while maintaining the rigorous scientific standards that have defined its growth trajectory to date.
See full RefleXion company page
